- Mimrylo is approved for adults whose polycythemia vera remains inadequately controlled with existing therapies and frequent phlebotomies.
- In the 293-patient VERIFY phase 3 trial, 76.9% of Mimrylo-treated patients required no phlebotomies during the measured period, versus 32.9% of placebo patients.
- The most common adverse reactions were injection-site reactions and anemia; Takeda Pharmaceuticals America received the approval.
Quotes
“Today's approval of Mimrylo offers a new, first-in-class option that has the potential to meaningfully reduce patient burden.”